Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 4406

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Therapeutic
  • Drug delivery
  • cell therapy
  • Disease
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4406

License Grant
In 2005 Licensor and Licensee entered into a collaboration to develop the Captisol-enabled IV formulation of Carfilzomib for refractory multiple myeloma.
License Property
In July 2012, Licensee received accelerated approval from the FDA for Kyprolis (Carfilzomib) for injection.  Kyprolis is formulated with Licensor’s Captisol and is used for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 60409

License Grant
The agreement grants an exclusive license under the patent rights to Captisol relating to the product.
License Property
The related product, Evomela, is a Captisol-enabled melphalan IV formulation.  The Evomela formulation avoids the use of propylene glycol, which has been reported to cause renal and cardiac side-effects that limit the ability to deliver higher quantities of therapeutic compounds. The use of the Captisol technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.
Field of Use
Evomela is intended for use in the multiple myeloma stem cell transplant setting, and has been granted Orphan Designation by the FDA.

IPSCIO Record ID: 25926

License Grant
Licensor entered into a License Agreement with a privately-held company granting it an exclusive worldwide license for the development and commercialization of Captisol-enabledâ„¢ Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.  A successful Phase 1 clinical trial of Captisol-enabled Topiramate Injection has already been completed, and licensee has announced that it intends to commence a Phase II clinical trial during 2014.
License Property
The Captisol-enabled Topiramate Injection formulation is designed to provide an intravenous or intramuscular option for hospitalized epilepsy patients unable to use oral topiramate.  Captisol® is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.

IPSCIO Record ID: 3986

License Grant
The two parties have a collaborative license agreement regarding a new drug for the treatment of multiple myeloma.

Elotuzumab, a CS1 directed antibody, is in phase 1 development for the treatment of multiple myeloma. The Company and Licensee presented promising new data from studies of elotuzumab in patients with MM at the American Society of Hematology conference in December 2009.  PDL241.  PDL241 is in pre-clinical development for immunologic diseases.  Like elotuzumab, PDL241 is directed against the CS1 antigen. The Licensee has an option to include PDL241 in the existing collaboration with the Licensor.

Field of Use
The rights granted apply to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.